The Herbert Irving Comprehensive Cancer Center (HICCC) was designated an NCI Cancer Center in 1972 and gained comprehensive status in 1979. The HICCC is a component of Columbia University Medical Center and associated with New York-Presbyterian Hospital (NYPH). During the period 2003-07, CUMC and NYPH have committed over $312.7 million for i) new research initiatives in basic, clinical and population science;ii) new and expanded facilities for laboratory research and clinical activities;iii) recruitment and program restructuring;iv) support of the Center's administrative office;and v) bridge funding to offset reduced NCI CCSG support. A new Director, Riccardo Dalla-Favera, MD, was appointed in 2005 and given: i) authority over new facilities, including the Irving Cancer Research Center (ICRC), a new 10-story building dedicated to cancer research, with state-of-the-art laboratories (100,000 square feet) and incremental clinical (30,000 square feet) space in the Herbert Irving Pavilion (HIP);ii) a broad-based recruitment plan, which has already attracted 8 new faculty members to the HICCC;and iii) restructuring and expansion of the shared resources. The Director has fully reshaped the senior leadership of the HICCC with appointments of a Deputy Director for Clinical Research and Associate Directors for Basic Research, Clinical Research, Population Science, Biomedical Informatics, Shared Resources and Administration. The programmatic structure of the HICCC has been reorganized to increase cancer focus and interdisciplinary collaboration, and now includes 216 members from 22 Departments and 6 Schools, assigned to two Basic Research programs (Cancer Signaling Networks and Cancer Genetics &Epigenetics), three Disease-Specific programs (Breast Cancer, Prostate Cancer, and Lymphoid Development &Malignancy), and two Population Science programs (Cancer Epidemiology and Prevention, Control &Disparities). The HICCC administers and supports a total of 12 Shared Resources, of which four have been recently created.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013696-39S1
Application #
8518702
Study Section
Subcommittee G - Education (NCI)
Program Officer
Adjei, Brenda A
Project Start
1997-07-04
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
39
Fiscal Year
2012
Total Cost
$140,000
Indirect Cost
$52,500
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Sones, Jennifer L; Merriam, Audrey A; Seffens, Angelina et al. (2018) Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia. FASEB J 32:2574-2586
Park, Karen Sophia; Xu, Christine L; Cui, Xuan et al. (2018) Reprogramming the metabolome rescues retinal degeneration. Cell Mol Life Sci 75:1559-1566
Mumau, Melanie D; Vanderbeck, Ashley N; Lynch, Elizabeth D et al. (2018) Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1. J Immunol 200:1078-1087
Savage, Thomas M; Shonts, Brittany A; Obradovic, Aleksandar et al. (2018) Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 3:
Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429
Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549
Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205
Yen, Bonnie; Fortson, Katherine T; Rothman, Nyanza J et al. (2018) Clonal Bifurcation of Foxp3 Expression Visualized in Thymocytes and T Cells. Immunohorizons 2:119-128
Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406
Jin, Chun-Hui; Li, Yang; Xia, Jinxing et al. (2018) CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol 93:786-793

Showing the most recent 10 out of 331 publications